ClinicalTrials.gg

Program

Tegafur

Also written as “S-1”, “S-1/Cisplatin” and “S-1, Irinotecan, Bevacizumab”.

Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Renal Insufficiency, led by 4 companies.

Furthest: phase 3, since Jun 30, 200525 company-led studies, 1 open or runningNext primary completion: Jun 30, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka190 open or runningphase 3since Jun 30, 2005Jun 30, 2005none ahead
TTY Biopharm40 open or runningphase 2since Mar 26, 2015Jun 4, 2013none ahead
Innovent Biologics11 open or runningphase 2since Mar 16, 2026Mar 16, 2026Jun 30, 2030phase 2 · NCT07483567
Sanofi10 open or runningphase 3since Jan 16, 2008Jan 16, 2008none ahead

Also a collaborator on its studies: quintiles-inc, united-biosource-llc and Daiichi Sankyo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Jun 30, 2005.

  1. Jan 30, 2006Phase 3 study in Colorectal NeoplasmsOtsuka · NCT00284258 · 426 enrolled · Japan
  2. Nov 8, 20063 phase 1 studiesOtsuka · NCT00398424, NCT00398307, NCT00400023
  3. Jul 6, 2007Phase 3 study in Pancreatic NeoplasmsOtsuka · NCT00498225 · 834 enrolled · Japan, Taiwan
  4. Dec 5, 20073 phase 2 studiesOtsuka · NCT00569790, NCT00569699, NCT00569335
  5. Jan 16, 2008Sanofi's first study: phase 3 study in Pancreatic NeoplasmsNew to SanofiSanofi · NCT00602745 · 61 enrolled · United States, Austria, Brazil and more
  6. Mar 31, 20084 phase 2 studiesOtsuka · NCT00652561, NCT00652054, NCT00651833 and 1 more
  7. Oct 9, 2008Phase 3 study in Uterine Cervical NeoplasmsOtsuka · NCT00770874 · 375 enrolled · Japan, Korea, Republic of, Taiwan
  8. Apr 30, 2009Phase 2 study in Colorectal NeoplasmsOtsuka · NCT00891332 · 73 enrolled · China, Japan
  9. Jan 26, 2011Phase 3 study in Stomach NeoplasmsOtsuka · NCT01285557 · 361 enrolled · United States, Argentina, Belgium and more
  10. Jun 4, 2013TTY Biopharm's first study: no phase study in Carcinoma, Non-Small-Cell LungNew to TTY BiopharmTTY Biopharm · NCT01874678 · 45 enrolled · Taiwan
  11. Mar 26, 2015Phase 2 study in Advanced Biliary Tract Cancer(BTC)TTY Biopharm · NCT02425137 · 51 enrolled · Taiwan
  12. Apr 12, 2018Phase 2 study in Colorectal NeoplasmsTTY Biopharm · NCT03517618 · 41 enrolled · Taiwan
  13. Aug 20, 2019Phase 2 study in Pancreatic NeoplasmsTTY Biopharm · NCT04070313 · 36 enrolled · Taiwan
  14. Mar 16, 2026Innovent Biologics's first study: phase 2 study in CLDN18.2 PositiveNew to Innovent BiologicsInnovent Biologics · NCT07483567 · 90 planned · China

Ahead

  1. Jun 30, 2030Primary completion: phase 2 study in CLDN18.2 PositiveInnovent Biologics · NCT07483567

TargetBeta

TYMS →read by rule
“RNA inhibitor; Thymidylate synthase inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
CapecitabineruleHoffmann-La Rochephase 4129
FluorouracilruleSanofiphase 482

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07483567CLDN18.2 Positive · China2RecruitingInnovent BiologicsJun 30, 203090
NCT04070313Pancreatic Neoplasms · Taiwan2TerminatedTTY BiopharmOct 31, 202136
NCT03517618Colorectal Neoplasms · Taiwan2CompletedTTY BiopharmJun 18, 201541
NCT02425137Advanced Biliary Tract Cancer(BTC) · Taiwan2CompletedTTY BiopharmMay 201751
NCT01874678Carcinoma, Non-Small-Cell Lung · Taiwan–CompletedTTY BiopharmDec 201545
NCT01285557Stomach Neoplasms · United States, Argentina, Belgium and more3TerminatedOtsukaAug 15, 2014361
NCT00891332Colorectal Neoplasms · China, Japan2CompletedOtsukaJul 201173
NCT00770874Uterine Cervical Neoplasms · Japan, Korea, Republic of, Taiwan3CompletedOtsukaDec 2015375
NCT00652561Advanced Non-Small Cell Lung Cancer2CompletedOtsukaNov 200757
NCT00652054Pancreatic Neoplasms2CompletedOtsukaJun 200739
NCT00651833Advanced Non-Small Cell Lung Cancer2CompletedOtsukaOct 200660
NCT00651742Pancreatic Neoplasms2CompletedOtsukaJul 8, 200828
NCT00602745Pancreatic Neoplasms · United States, Austria, Brazil and more3TerminatedSanofiMar 201061
NCT00569790Colorectal Neoplasms · Japan2CompletedOtsukaMar 201053
NCT00569699Colorectal Neoplasms · Japan2CompletedOtsukaMar 201156
NCT00569335Colonic Neoplasms · Japan2CompletedOtsukaMar 201052
NCT00498225Pancreatic Neoplasms · Japan, Taiwan3CompletedOtsukaJul 2011834
NCT00400023Neoplasms · United States1CompletedOtsukaMay 200712
NCT00398424Impaired Hepatic Function · United States1CompletedOtsukaNov 200824
NCT00398307Renal Insufficiency · United States1CompletedOtsukaSep 201024
NCT00284258Colorectal Neoplasms · Japan3CompletedOtsukaJul 2010426
NCT00202969Stomach Neoplasms · China3CompletedOtsukaJan 2007180
NCT00152217Stomach Neoplasms · Japan3CompletedOtsukaMay 20071,000
NCT00150670Stomach Neoplasms · Japan3CompletedOtsukaDec 2006300
NCT00400179Stomach Neoplasms · United States, Canada3CompletedOtsukaMar 20081,053

How it is read

Names in the registry

  • “S-1”, 8 entries
  • “S-1/Cisplatin”, 3 entries
  • “S-1, Irinotecan, Bevacizumab”, 2 entries
  • “IBI343,sintilimab,oxaliplatin,S-1”, 1 entry
  • “S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.